Premium
P3‐262: SLEEP AND BRAIN AMYLOID LOAD IN FRAIL PARTICIPANTS: A COMPLEX RELATIONSHIP
Author(s) -
Gabelle Audrey,
Gutierrez Laure Anne,
Jaussent Isabelle,
Ben Bouallegue Fayçal,
De Verbizier Delphine,
Navucet Sophie,
Grasselli Caroline,
Bennys Karim,
Marelli Cecilia,
David Renaud,
Mariano-Goulart Denis,
Andrieu Sandrine,
Vellas Bruno,
Payoux Pierre,
Berr Claudine,
Dauvilliers Yves
Publication year - 2018
Publication title -
alzheimer's and dementia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 6.713
H-Index - 118
eISSN - 1552-5279
pISSN - 1552-5260
DOI - 10.1016/j.jalz.2018.06.1622
Subject(s) - epworth sleepiness scale , precuneus , excessive daytime sleepiness , medicine , polysomnography , confounding , geriatric depression scale , insomnia , psychology , sleep disorder , endocrinology , psychiatry , depressive symptoms , cognition , diabetes mellitus , apnea
symptom onset in familial Alzheimer’s disease (FAD) and correlates with rates of whole brain atrophy (Weston et al., 2017); however, associations with downstream cognitive change have not been explored. We investigated whether baseline serum NfL concentration is associated with subsequent rate of cognitive decline. Methods: Forty-seven individuals from families with PSEN1 or APP mutations were recruited: 17 had symptomatic AD and 30 were asymptomatic but at 50% risk of carrying a mutation. Estimated years from symptom onset (EYO) was calculated by subtracting the age at which the participant’s affected parent first displayed progressive cognitive symptoms from the participant’s age at NfL sampling. Serum NfL concentrations were measured using an in house Single molecule array (Simoa) assay. Participants had at least one cognitive assessment (mean1⁄4 2.7) including MMSE, CDR, Trails A and B, Recognition Memory Test (RMT) for words and faces and verbal and performance IQ. Spearman coefficients tested for associations between baseline serum NfL and annualised rates of change in cognitive measures, which were calculated over a maximum interval of three years from initial assessment Results: Nineteen of the asymptomatic participants were mutation carriers (mean EYO1⁄4 9.6 years); eleven were non-carriers (demographics in Table). Serum NfL concentration was higher in both symptomatic (mean 1⁄4 46.2621.4 pg/ml) and presymptomatic mutation carriers (mean 1⁄4 16.767.7 pg/ml) than in non-carrier controls (mean 1⁄4 12.767.2 pg/ml). There was evi-